• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.07% Nasdaq Up0.32%

    China Biologic Products, Inc. (CBPO)

    -NasdaqGS
    100.21 Up 0.37(0.37%) Aug 28, 4:00PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    China Biologic Products, Inc.
    Jialong International Tower
    18th Floor
    Beijing, 100125
    China - Map
    Phone: 86 10 6598 3111
    Website: http://www.chinabiologic.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:1,621

    Business Summary 

    China Biologic Products, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also offers human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human immunoglobulin and immunoglobulin for intravenous injection products for original and secondary immunoglobulin deficiency, and auto-immune deficiency diseases; and Thymopolypeptides injection for the treatment of original and secondary T-cell deficiency syndromes, auto-immune deficiency diseases, and cell immunity deficiency diseases, as well as assists in the treatment for tumors. In addition, it provides human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; human tetanus immunoglobulin for the prevention and therapy of tetanus; placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; human coagulation factor VIII for treating coagulopathie; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing human hepatitis B immunoglobulin (PH4) for intravenous injection; human fibrinogen; immune globulin intravenous; human antithrombin III; and human cytomegalovirus immunoglobulin. It distributes its products directly or through distributors. The company is headquartered in Beijing, the People's Republic of China.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on China Biologic Products, Inc.

    Key Executives 
     PayExercised
    Mr. Xiaoying Gao , 64
    Exec. Chairman, Chief Exec. Officer and Pres
    N/AN/A
    Mr. Ming Yang , 43
    Chief Financial Officer
    567.00K0.00
    Mr. Ming Yin , 37
    Sr. Corp. VP and Corp. Sec.
    335.00K0.00
    Ms. Zhijing Liu , 61
    Corp. VP
    N/AN/A
    Mr. Gang Yang , 50
    Corp. VP and Gen. Mang. of Guizhou Taibang
    362.00K0.00
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders